Table C76Odds ratio and attributable events of clinical outcomes after different treatments I patients with localized prostate cancer

DesignQualityStudies ReferenceActiveControlOutcomesEffect: Odds Ratio (95%CI)Attributable Fraction of Events (%)Rate (%) in Active GroupRate (%) in Control GroupNNTNumber of Avoided (Excessive) Events per 1,000 Hospitalized
RCTModerateBill-Axelson, 2005 179 Radical prostatectomy at 10 yearsWatchful waiting at 10 yearsOverall mortality0.74 (0.56; 0.99)**2627322050
RCTModerateWirth, 2004 19 Bicalutamide and watchful waitingPlacebo and adjuvant therapyOverall mortality1.31 (1.04; 1.65)23.73020-21-47
RCTModerateZietman, 2005 6 External beam radiation: high dose (79.2 Gy)External beam radiation: conventional dose (70 Gy)3 consecutive increases in PSA level, with the failure backdated to a point halfway between the first increase and the last non-increasing value0.40 (0.25; 0.62)60.520405190
RCTModerateD'Amico, 2004 8 Conformal radiation therapy and androgen suppression therapyConformal radiation therapy (70 Gy)PSA >1.0 ng/ml and increasing >0.2 ng/ml on 2 consecutive visits0.34 (0.18; 0.63)66.220404232
RCTModeratePaulson, 1982 13 Radical prostatectomyRadiation therapyAcid phosphatase elevation on 2 consecutive followups or by appearance of bony or parenchymal disease with or without concomitant acid phosphatase elevation0.27 (0.11; 0.71)72.610404250
RCTModerateSathya, 2005 15 EBRTIridium implant + EBRTPSA failure, clinical failure3.70 (1.27; 10.73)72.96030-3-315

From: Appendix C, Evidence Tables and Figures

Cover of Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer
Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer [Internet].
Comparative Effectiveness Reviews, No. 13.
Wilt TJ, Shamliyan T, Taylor B, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.